Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MANE
MANE logo

MANE Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
66.199
Open
62.530
VWAP
63.98
Vol
538.67K
Mkt Cap
2.37B
Low
62.240
Amount
34.46M
EV/EBITDA(TTM)
--
Total Shares
37.34M
EV
2.47B
EV/OCF(TTM)
--
P/S(TTM)
--
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Show More

Events Timeline

(ET)
2026-03-02
11:30:00
Generate Biomedicines Debuts with 6% Price Increase
select
2026-02-09 (ET)
2026-02-09
11:10:00
SpyGlass Pharma Surges Over 60% on First Trading Day
select
2026-02-09
07:40:00
Veradermics Completes Enrollment in Second Phase 3 Trial for VDPHL01
select
2026-02-04 (ET)
2026-02-04
13:30:00
Veradermics Prices 15.08M Shares at $17.00
select

News

renaissancecapital
8.5
03-02renaissancecapital
February IPO Market Review and Outlook
  • Strong Fundraising: In February, 13 IPOs raised a total of $4.4 billion, surpassing the historical average over the past decade, indicating sustained investor interest in new listings despite market volatility.
  • Market Volatility Impact: Although IPO activity was robust at the beginning of February, concerns over AI disruption led to a sell-off in tech stocks mid-month, resulting in price cuts and postponements for some high-profile IPOs, reflecting market uncertainty.
  • Return Performance: The average return for IPOs this month was 22%, with those raising over $100 million achieving an impressive 28%, suggesting that investors remain optimistic about growth potential in the biotech and consumer sectors.
  • Optimistic Future Outlook: Despite a decline in new filing activity, stabilizing market conditions are expected to encourage a gradual increase in IPO issuance in March, particularly given the strong performance of recent listings.
Barron's
3.5
02-12Barron's
Anthropic's Valuation Reaches $380 Billion as AI Thrives Amid Software Struggles
  • Software vs. AI: The article discusses the ongoing competition between traditional software and artificial intelligence, highlighting that software is struggling to keep up with advancements in AI technology.

  • Impact on Industries: The rise of AI is transforming various industries, leading to a shift in how tasks are performed and potentially displacing traditional software solutions.

  • Future of Development: As AI continues to evolve, the future of software development may increasingly rely on integrating AI capabilities, changing the landscape of programming and application design.

  • Challenges for Software: The article emphasizes the challenges faced by software developers in adapting to the rapid changes brought about by AI, which may require new skills and approaches to remain relevant.

Newsfilter
8.5
02-09Newsfilter
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss
  • Trial Enrollment Completion: Veradermics announced the completion of enrollment for its second Phase 3 clinical trial of VDPHL01 targeting male pattern hair loss, with over 1,000 participants, marking a significant milestone that is expected to facilitate the submission of a new drug application.
  • Data Release Expectations: Topline data from the initial '302' trial is anticipated in the first half of 2026, while confirmatory study '304' data is expected in the second half, providing critical efficacy and safety information that could influence FDA approval decisions.
  • Innovative Drug Potential: If approved, VDPHL01 would be the first non-hormonal oral treatment option for an estimated 50 million men and 30 million women in the U.S., addressing a significant market gap that has persisted for nearly 30 years, indicating substantial market potential.
  • Technological Advantage: The extended-release formulation of VDPHL01 aims to maximize minoxidil's hair growth effects while minimizing cardiac side effect risks, which is expected to enhance patient adherence to treatment and position the product favorably in the competitive hair restoration market.
Barron's
8.5
02-06Barron's
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
  • Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.

  • Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.

  • Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.

  • Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.

Barron's
7.0
02-06Barron's
Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.
  • Amazon's Spending Forecast: Amazon's recent spending forecast has surprised the markets, contrasting sharply with the prevailing risk-averse sentiment among investors.

  • Concerns Over AI Investments: This situation raises concerns about whether the current enthusiasm for artificial intelligence investments may mirror the speculative excesses seen during the dot-com bubble.

Barron's
8.5
02-05Barron's
Three Companies Make Their Debut Today as the IPO Market Gains Momentum: SpaceX, OpenAI, and Anthropic on the Horizon.
  • Upcoming IPOs: Three new IPOs are set to launch today, attracting investor attention.

  • Key Players: The companies involved in these IPOs include SpaceX, OpenAI, and Anthropic.

  • Market Anticipation: Investors are particularly eager for these IPOs as they await significant developments later this year.

  • Investment Climate: The current market environment is buzzing with excitement over these high-profile companies entering the public market.

Wall Street analysts forecast MANE stock price to rise
0 Analyst Rating
Wall Street analysts forecast MANE stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
Cantor Fitzgerald
Prakhar Agrawal
Overweight
initiated
AI Analysis
2026-03-02
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
AI Analysis
2026-03-02
initiated
Overweight
Reason
As previously reported, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Veradermics with an Overweight rating and no price target. Veradermics is a late clinical-stage biotech focused on dermatology and aesthetic conditions, the analyst tells investors in a research note. The firm says the company has leveraged the "validated biology" of minoxidil for pattern hair loss and optimized its pharmacokinetics to improve efficacy and reduce safety risks. Cantor sees a large total addressable market for minoxidil says there has recently been an inflection in demand for pattern hair loss products.
Jefferies
initiated
$75
2026-03-02
Reason
Jefferies
Price Target
$75
2026-03-02
initiated
Reason
Jefferies initiated coverage of Veradermics with a Buy rating and $75 price target. The firm thinks the company's Phase 3 study has a high likelihood of success. The company's VDPHL01 extended release enables sustained plasma concentrations, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MANE
Unlock Now

Valuation Metrics

The current forward P/E ratio for Veradermics Inc (MANE.N) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Veradermics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding MANE

S
Suvretta Capital Management, LLC
Holding
MANE
-10.41%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Veradermics Inc (MANE) stock price today?

The current price of MANE is 63.49 USD — it has increased 2.54

What is Veradermics Inc (MANE)'s business?

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

What is the price predicton of MANE Stock?

Wall Street analysts forecast MANE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MANE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Veradermics Inc (MANE)'s revenue for the last quarter?

Veradermics Inc revenue for the last quarter amounts to -5.97M USD, decreased

What is Veradermics Inc (MANE)'s earnings per share (EPS) for the last quarter?

Veradermics Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Veradermics Inc (MANE). have?

Veradermics Inc (MANE) has 19 emplpoyees as of March 25 2026.

What is Veradermics Inc (MANE) market cap?

Today MANE has the market capitalization of 2.37B USD.